🇺🇸 FDA

Company profile · Sponsor

Mirum

Mirum Pharmaceuticals International B.V.

MIRM · NYSE pharma FOSTER CITY, CA, EU
Pipeline
24
Drugs
3
Patents
4

Quick answer

Mirum (MIRM) is a pharma company. headquartered in FOSTER CITY, CA, EU. listed on NYSE. NovaPharmaNews links 24 pipeline programs, 3 drugs, and 4 patents to this profile..

Company facts

Ticker MIRM
Exchange NYSE
Company type pharma
Headquarters FOSTER CITY, CA, EU
SEC CIK 0001759425

Pipeline (24)

Search pipeline →

  1. Blinded CDCA 250 mg TID

    Mirum

    CTX

    phase 3 small molecule completed

    1 trial

  2. Brelovitug (BJT-778)

    Mirum

    Chronic Hepatitis D

    phase 3 small molecule active

    1 trial

  3. Brelovitug 300 mg

    Mirum

    Chronic Hepatitis D Infection

    phase 3 small molecule active

    3 trials

  4. Cholic Acid

    Mirum

    Bile Acid Synthesis Defect

    phase 3 small molecule completed

    1 trial

  5. Cholic Acids

    Mirum

    Infantile Refsum's Disease

    phase 3 small molecule completed

    1 trial

  6. Cholic acid

    Mirum

    Inborn Errors of Bile Acid Synthesis

    phase 3 small molecule completed

    1 trial

  7. Maralixibat

    Mirum

    Progressive Familial Intrahepatic Cholestasis (PFIC)

    phase 3 small molecule terminated

    3 trials

  8. Maralixibat

    Mirum

    Cholestatic Liver Disease (Except ALGS, PFIC, PBC and PSC)

    phase 3 small molecule active

    1 trial

  9. LUM001

    Mirum

    Primary Biliary Cirrhosis

    phase 2 small molecule terminated

    1 trial

  10. LUM001

    Mirum

    Alagille Syndrome

    phase 2 small molecule completed

    2 trials

  11. LUM001

    Mirum

    PBC

    phase 2 small molecule completed

    1 trial

  12. LUM001

    Mirum

    Primary Sclerosing Cholangitis (PSC)

    phase 2 small molecule completed

    1 trial

  13. LUM001 (Maralixibat)

    Mirum

    Progressive Familial Intrahepatic Cholestasis (PFIC)

    phase 2 small molecule completed

    1 trial

  14. LUM001 (Maralixibat)

    Mirum

    Alagille Syndrome

    phase 2 small molecule completed

    3 trials

  15. Low dose of MRM-3379

    Mirum

    Fragile X Syndrome

    phase 2 small molecule active

    1 trial

  16. Maralixibat

    Mirum

    Intrahepatic Cholestasis of Pregnancy

    phase 2 small molecule active

    1 trial

  17. Maralixibat

    Mirum

    Progressive Familial Intrahepatic Cholestasis

    phase 2 small molecule completed

    1 trial

  18. Maralixibat

    Mirum

    Biliary Atresia

    phase 2 small molecule completed

    1 trial

  19. Maralixibat

    Mirum

    Cholestatic Liver Disease

    phase 2 small molecule completed

    1 trial

  20. SHP626

    Mirum

    Non-Alcoholic Steatohepatitis

    phase 2 small molecule completed

    3 trials

  21. Volixibat

    Mirum

    Intrahepatic Cholestasis of Pregnancy

    phase 2 small molecule terminated

    1 trial

  22. Volixibat

    Mirum

    Primary Sclerosing Cholangitis

    phase 2 small molecule active

    1 trial

  23. Volixibat

    Mirum

    Primary Biliary Cholangitis

    phase 2 small molecule active

    1 trial

  24. Placebo

    Mirum

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

Drugs (3)

Search drugs →

  1. chenodiol

    CHENIX

    ORAL approved

  2. cholic acid

    ORPHACOL

    ORAL approved

    A05AA03

  3. maralixibat chloride

    LIVMARLI

    ORAL approved

    A05AX04

Patents (4)

Search patents →

  1. US 12296050

    Pharmaceutical compositions comprising maralixibat and uses thereof

    Expires Mon May 08 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 11918578

    Methods for treating cholestasis

    Expires Mon Feb 29 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 11497745

    Methods for treating cholestasis

    Expires Mon Nov 10 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11229647

    Methods for treating cholestasis

    Expires Mon Jan 20 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is Mirum?

Mirum (MIRM) is a pharma company. headquartered in FOSTER CITY, CA, EU. listed on NYSE. NovaPharmaNews links 24 pipeline programs, 3 drugs, and 4 patents to this profile..

What pipeline programs does Mirum sponsor?

We track 24 ClinicalTrials.gov-linked programs for Mirum, including Blinded CDCA 250 mg TID and 23 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Mirum company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.